<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04458259</url>
  </required_header>
  <id_info>
    <org_study_id>C4201002</org_study_id>
    <secondary_id>ARRAY-067-102</secondary_id>
    <secondary_id>2021-004270-59</secondary_id>
    <nct_id>NCT04458259</nct_id>
  </id_info>
  <brief_title>Study of PF-07265807 in Participants With Metastatic Solid Tumors.</brief_title>
  <official_title>A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF-07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as&#xD;
      Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">January 23, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 23, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation and expansion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parts 1, 2, and 3: Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>Baseline through day 21 or 42</time_frame>
    <description>DLTs will be evaluated during the first cycle (day 21) or two cycles (day 42). The number of DLTs will be used to determine the maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1, 2 and 3: Number of participants with treatment emergent adverse events (AEs)</measure>
    <time_frame>Baseline through approximately 2 years</time_frame>
    <description>AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1, 2, and 3: Number of participants with laboratory abnormalities</measure>
    <time_frame>Baseline through approximately 2 years</time_frame>
    <description>Laboratory abnormalities as characterized by type, frequency, severity, and timing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 4: Overall Response Rate (ORR)</measure>
    <time_frame>Baseline through approximately 2 years</time_frame>
    <description>Response will be evaluable via radiographical tumor assessment by RECIST v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 4: Complete Response (CR)</measure>
    <time_frame>Baseline through approximately 2 years</time_frame>
    <description>Response will be evaluated via radiographical tumor assessment by RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2, and 3: Maximum plasma concentration (Cmax) and dose normalized (Cmax(dn))</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 hours post dose; Day 7 predose and 2 hours post dose; Cycle 2 Days 1 and 14, predose and 2 hours post dose; Cycles 3-6 Days 1 and 14 predose</time_frame>
    <description>Single dose (Cmax / Cmax(dn)) and multiple dose (assuming steady state is achieved; Cmax,ss / Cmax,ss(dn)) pharmacokinetic (PK) parameters of PF-07265807, its metabolite, sasanlimab, or axitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2, and 3: Time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 hours post dose; Day 7 predose and 2 hours post dose; Cycle 2 Days 1 and 14, predose and 2 hours post dose; Cycles 3-6 Days 1 and 14 predose</time_frame>
    <description>Single dose (Tmax) and multiple dose (assuming steady state is achieved; Tmax,ss) pharmacokinetic parameters of PF-07265807, its metabolite, sasanlimab, or axitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2, and 3: Minimum plasma concentration (Cmin)</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 hours post dose; Day 7 predose and 2 hours post dose; Cycle 2 Days 1 and 14, predose and 2 hours post dose; Cycles 3-6 Days 1 and 14 predose</time_frame>
    <description>Single dose (Cmin) and multiple dose (assuming steady state is achieved; Cmin,ss) pharmacokinetic parameters of PF-07265807, its metabolite, sasanlimab, or axitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2, and 3: Average observed concentration (Cavg)</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 hours post dose; Day 7 predose and 2 hours post dose; Cycle 2 Days 1 and 14, predose and 2 hours post dose; Cycles 3-6 Days 1 and 14 predose</time_frame>
    <description>Single dose (Cavg) and multiple dose (assuming steady state is achieved; Cavg,ss) pharmacokinetic parameters of PF-07265807, its metabolite, sasanlimab, or axitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2, and 3: Area under the curve from the time of dose to the last measurable concentration (AUClast) and dose normalized (AUClast(dn))</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 hours post dose; Day 7 predose and 2 hours post dose; Cycle 2 Days 1 and 14, predose and 2 hours post dose; Cycles 3-6 Days 1 and 14 predose</time_frame>
    <description>Single dose (AUClast and AUClast(dn)) pharmacokinetic parameters of PF-07265807, its metabolite, sasanlimab, or axitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2, and 3: Area under the curve from the time of dose to the time of the subsequent dose (AUCtau) and dose normalized (AUCtau(dn))</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 hours post dose; Day 7 predose and 2 hours post dose; Cycle 2 Days 1 and 14, predose and 2 hours post dose; Cycles 3-6 Days 1 and 14 predose</time_frame>
    <description>Multiple dose assuming steady state is achieved (AUCtau,ss and AUCtau,ss(dn)) and single dose (as data permits; AUCtau) pharmacokinetic parameters of PF-07265807, its metabolite, sasanlimab, or axitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2, and 3: Terminal elimination half-life (t1/2)</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 hours post dose; Day 7 predose and 2 hours post dose; Cycle 2 Days 1 and 14, predose and 2 hours post dose; Cycles 3-6 Days 1 and 14 predose</time_frame>
    <description>As data permits, single dose (t1/2) pharmacokinetic parameters of PF-07265807, its metabolite, sasanlimab, or axitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2, and 3: Area under the curve from the time of dose extrapolated to infinity (AUCinf) and dose normalized (AUCinf(dn))</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 hours post dose; Day 7 predose and 2 hours post dose; Cycle 2 Days 1 and 14, predose and 2 hours post dose; Cycles 3-6 Days 1 and 14 predose</time_frame>
    <description>As data permits, single dose (AUCinf and AUCinf(dn)) pharmacokinetic parameters of PF-07265807, its metabolite, sasanlimab, or axitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2, and 3: Apparent oral clearance (CL/F)</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 hours post dose; Day 7 predose and 2 hours post dose; Cycle 2 Days 1 and 14, predose and 2 hours post dose; Cycles 3-6 Days 1 and 14 predose</time_frame>
    <description>Single dose (CL/F) and multiple dose (as data permits) pharmacokinetic parameters of PF-07265807, its metabolite, sasanlimab, or axitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2, and 3: Apparent terminal volume of distribution (Vz/F)</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 hours post dose; Day 7 predose and 2 hours post dose; Cycle 2 Days 1 and 14, predose and 2 hours post dose; Cycles 3-6 Days 1 and 14 predose</time_frame>
    <description>As data permits, single dose (Vz/F) and multiple dose (Vss/F) pharmacokinetic parameters of PF-07265807, its metabolite, sasanlimab, or axitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2, and 3: Accumulation ratio area under the curve (Rac,auc) and of maximum observed concentration (Rac,cmax)</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 hours post dose; Day 7 predose and 2 hours post dose; Cycle 2 Days 1 and 14, predose and 2 hours post dose; Cycles 3-6 Days 1 and 14 predose</time_frame>
    <description>As data permits, multiple dose (Rac,auc and Rac,cmax) pharmacokinetic parameters of PF-07265807, its metabolite, sasanlimab, or axitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2, and 3: ORR</measure>
    <time_frame>Baseline through approximately 2 years</time_frame>
    <description>Response will be evaluable via radiographical tumor assessment by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 4: Number of participants with treatment emergent AEs</measure>
    <time_frame>Baseline through approximately 2 years</time_frame>
    <description>AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 4: Number of participants with laboratory abnormalities</measure>
    <time_frame>Baseline through approximately 2 years</time_frame>
    <description>Laboratory abnormalities as characterized by type, frequency, severity, and timing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part4: PF-07265807 and its metabolite Pharmacokinetic (PK) concentration</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 2, and 4 hours post dose. Day 7 predose and 2 hours post dose; Cycles 2-6 Days 1 and 14: predose</time_frame>
    <description>PK concentrations of PF-07265807 and its metabolite: Predose/trough concentration (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part4: PF-07265807 and its metabolite PK concentration</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 2, and 4 hours post dose. Day 7 predose and 2 hours post dose; Cycles 2-6 Days 1 and 14: predose</time_frame>
    <description>PK concentrations of PF-07265807 and its metabolite: Post dose concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 4, Cohorts 2-4: Sasanlimab PK concentration</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Days 1, 7, and 14: predose; Cycles 2-6 Day 1: predose.</time_frame>
    <description>PK concentrations of sasanlimab: predose/trough concentration (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 4, Cohort 4: Axitinib PK concentration</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Day 1: predose; Cycle 1 Day 14: predose, 2, and 4 hours post dose</time_frame>
    <description>PK concentrations of axitinib: predose/trough concentration (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of sasanlimab when given in combination</measure>
    <time_frame>Each cycle is 21 days. Cycle 1 Day 1 predose; Cycle 6 Day 1 predose; Cycle 13 Day 1 predose; and then Day 1 every 6 cycles</time_frame>
    <description>Incidence and titer of anti-sasanlimab ADA response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Baseline through approximately 2 years</time_frame>
    <description>Response will be evaluable via radiographical tumor assessment by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Baseline through approximately 2 years</time_frame>
    <description>Response will be evaluable via radiographical tumor assessment by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Baseline through approximately 2 years</time_frame>
    <description>Response will be evaluable via radiographical tumor assessment by RECIST v1.1</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Monotherapy Dose Escalation: Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy dose escalation of PF-07265807 in participants with select tumor types.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doublet Dose Escalation: Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doublet combination dose escalation of PF-07265807 with sasanlimab in participants with select tumor types. PF-07265807 will dose escalate. Sasanlimab dose will stay constant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triplet Dose Escalation: Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triplet combination dose escalation of PF-07265807 with sasanlimab plus axitinib in participants with RCC. PF-07265807 will dose escalate. Sasanlimab dose will stay constant. Axitinib dose will follow label.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase: Part 4, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07265807 monotherapy in participants with METex14 mutant NSCLC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase: Part 4, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07265807 with sasanlimab in participants with MSS CRC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase: Part 4, Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07265807 with sasanlimab in participants with PD-L1+ gastric cancer/GEJ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase: Part 4, Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07265807 with sasanlimab plus axitinib in participants with RCC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07265807</intervention_name>
    <description>Given QD 2 weeks on/1 week off</description>
    <arm_group_label>Doublet Dose Escalation: Part 2</arm_group_label>
    <arm_group_label>Expansion Phase: Part 4, Cohort 1</arm_group_label>
    <arm_group_label>Expansion Phase: Part 4, Cohort 2</arm_group_label>
    <arm_group_label>Expansion Phase: Part 4, Cohort 3</arm_group_label>
    <arm_group_label>Expansion Phase: Part 4, Cohort 4</arm_group_label>
    <arm_group_label>Monotherapy Dose Escalation: Part 1</arm_group_label>
    <arm_group_label>Triplet Dose Escalation: Part 3</arm_group_label>
    <other_name>ARRY-067</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sasanlimab</intervention_name>
    <description>Given SC 225 mg Q3W</description>
    <arm_group_label>Doublet Dose Escalation: Part 2</arm_group_label>
    <arm_group_label>Expansion Phase: Part 4, Cohort 2</arm_group_label>
    <arm_group_label>Expansion Phase: Part 4, Cohort 3</arm_group_label>
    <arm_group_label>Expansion Phase: Part 4, Cohort 4</arm_group_label>
    <arm_group_label>Triplet Dose Escalation: Part 3</arm_group_label>
    <other_name>PF-06801591; RN-888</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>Dosed per package label starting with 5 mg PO BID</description>
    <arm_group_label>Expansion Phase: Part 4, Cohort 4</arm_group_label>
    <arm_group_label>Triplet Dose Escalation: Part 3</arm_group_label>
    <other_name>AG-013736; Inlyta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least one measurable (Parts 1-4) or non-measurable lesion (Parts 1-3), not&#xD;
             previously irradiated, as defined by RECIST 1.1&#xD;
&#xD;
          -  ECOG Performance Status 0 or 1, 2 with approval&#xD;
&#xD;
          -  Adequate Bone Marrow Function&#xD;
&#xD;
          -  Adequate Renal Function&#xD;
&#xD;
          -  Adequate Liver Function&#xD;
&#xD;
          -  Resolved acute effects of any prior therapy&#xD;
&#xD;
          -  Able to provide adequate archival tumor tissue or freshly obtained tumor tissue (some&#xD;
             participants will require mandatory pre- and on-treatment biopsy is part of the&#xD;
             biomarker cohort).&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  Part 1 and Part 2: Participants who are intolerant or resistant to standard treatment&#xD;
             for selected solid tumors.&#xD;
&#xD;
          -  Part 3: Participants with advanced/metastatic RCC with a clear cell component and&#xD;
             progressed with no standard therapy available.&#xD;
&#xD;
          -  Part 4, Cohort 1: Participants with NSCLC with METex14-skipping alteration(s) and&#xD;
             progressed on at least 1 prior therapy.&#xD;
&#xD;
          -  Part 4, Cohort 2: Participants with MSS CRC with intermediate TMB and progressed with&#xD;
             no satisfactory alternative treatment available, but has not received prior treatment&#xD;
             with an anti-PD-(L)1 therapy.&#xD;
&#xD;
          -  Part 4, Cohort 3: Participants with metastatic gastric or GEJ adenocarcinoma that is&#xD;
             PD-L1 positive that has progressed on at least 2 but no more than 3 prior chemotherapy&#xD;
             regiments, but has not received prior treatment with an anti-PD-(L)1 therapy.&#xD;
&#xD;
          -  Part 4, Cohort 4: Participants with metastatic RCC with a clear cell component with&#xD;
             IMDC intermediate or poor risk that have not received any prior systemic therapy for&#xD;
             metastatic disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known active uncontrolled or symptomatic CNS metastases.&#xD;
&#xD;
          -  Any other active malignancy within 2 years prior to enrollment.&#xD;
&#xD;
          -  Major surgery within 6 weeks, radiation therapy within 4 weeks, systemic anti-cancer&#xD;
             therapy within 2 week or 5 half-lives (4 weeks or 5 half-lives for antibody therapies&#xD;
             or investigational drug(s) taken on another study) prior to study entry.&#xD;
&#xD;
          -  Active or history of autoimmune disease requiring &gt;10mg/day prednisone or other&#xD;
             concurrent immunosuppressive therapy.&#xD;
&#xD;
          -  Active, uncontrolled infection (controlled HBV, HCV, HIV/AIDS may be allowed) as&#xD;
             defined in protocol.&#xD;
&#xD;
          -  Retinal or other serious ophthalmic disorders as defined in protocol.&#xD;
&#xD;
          -  Clinically significant cardiac disease as defined in protocol.&#xD;
&#xD;
          -  Uncontrolled HTN that cannot be controlled by medications.&#xD;
&#xD;
          -  Inability to consume or absorb study drug.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to PF-07265807.&#xD;
&#xD;
          -  Prohibited concomitant medications as defined in protocol.&#xD;
&#xD;
          -  Active inflammatory GI disease, uncontrollable chronic diarrhea, or previous gastric&#xD;
             resection or lap band surgery affecting absorption.&#xD;
&#xD;
          -  Active bleeding disorder.&#xD;
&#xD;
        For Part 2, Part 3, and Part 4, Cohorts 2-4:&#xD;
&#xD;
          -  Known history of non-infectious pneumonitis that required steroid treatment or current&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Discontinuation of prior checkpoint inhibitor for treatment-related toxicity.&#xD;
&#xD;
          -  Experienced &gt;= G3 treatment-related irAE with prior PD-(L)1 agent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCI Medical Center- Outpatient Pharmacy</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCI/Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical &amp; Translational Science Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center - Mission Hall</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Investigational Drugs Pharmacy</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Lions Eye Institute (RMLEI)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas M. D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4201002</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 24, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAMK (TAM kinase)</keyword>
  <keyword>MER (mer proto-oncogene)</keyword>
  <keyword>MERTK (mer proto-oncogene tyrosine kinase)</keyword>
  <keyword>AXL (AXL receptor tyrosine kinase)</keyword>
  <keyword>AXL/MER</keyword>
  <keyword>Selective kinase inhibitor</keyword>
  <keyword>PD-1 (programmed cell death protein 1)</keyword>
  <keyword>PD-L1 (programmed cell death ligand 1)</keyword>
  <keyword>Immune modulator</keyword>
  <keyword>Advanced Cancer</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Solid Tumor Cancer</keyword>
  <keyword>Metastatic Solid Tumor</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Hepatocellular carcinoma (HCC)</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Merkel Cell Carcinoma</keyword>
  <keyword>High levels of MicroSatellite Instability deficient MisMatch Repair (MSI-H-dMMR) tumor</keyword>
  <keyword>Non-small cell lung cancer (NSCLC)</keyword>
  <keyword>Small cell lung cancer (SCLC)</keyword>
  <keyword>Renal cell carcinoma (RCC)</keyword>
  <keyword>Urothelial carcinoma</keyword>
  <keyword>Colorectal cancer (CRC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

